Adient 10-K: FY26 Sales $15.2B, Net Loss Narrows to $17M, Buyback Raised to $1B
ADNT is trading near its 52-week low of $15.58 (2.7% above the low).
Summary
Adient's fiscal 2026 10-K shows sales up 4.4% to $15.2 billion but a $17 million net loss after $108 million of restructuring charges, with $533 million of operating cash flow and a buyback authorization raised to $1 billion.
Key Events · Earnings and Guidance · ADNT
-
FY26 Sales Rise 4.4% to $15.2B
Net sales were $15,168 million versus $14,535 million, driven by $292 million of favorable foreign currency and higher Americas and Asia volumes, partly offset by lower EMEA production.
-
Net Loss Narrows to $17M
Net loss attributable to Adient was $17 million, or $(0.22) per diluted share, versus a $281 million loss in fiscal 2025 that included a $333 million EMEA goodwill impairment; gross margin slipped to 6.3% from 6.6%.
-
Cash Flow and Leverage
Operating cash flow was $533 million against $311 million of capital expenditures; total consolidated indebtedness was approximately $2.4 billion with $886 million of cash at September 30, 2026.
-
Buyback Authorization Raised to $1B
The board added $400 million in November 2026, bringing total authorization to $1 billion with $435 million remaining; Adient repurchased 4,877,462 shares for $100 million at an average of $20.50 in fiscal 2026.
Analysis · ADNT · Manufacturing
The annual report fills in the full fiscal 2026 picture behind the November 4 earnings release: sales rose 4.4% to $15,168 million, but gross margin slipped to 6.3% from 6.6% and the year still closed with a $17 million net loss attributable to Adient ($(0.22) per share) after $108 million of restructuring and impairment costs. Cash generation was the bright spot — $533 million from operations against $311 million of capex — and the balance sheet carries roughly $2.4 billion of debt against $886 million of cash. Two governance items matter for holders: the board added $400 million to the buyback (now $1 billion authorized, $435 million left), and the CEO adopted a 10b5-1 plan in August covering up to 20% of 179,305 vesting shares, a scheduled sale rather than a conviction signal. Goodwill of $1,808 million survived the annual test, but management flags that Americas and Asia fair values fell and sit only appreciably above carrying value — a warning that a weaker 2027 could bring impairment charges.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADNT was trading at $16.00 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $15.58 to $27.32. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.